Distress, disease, desire: perspectives on the medicalisation of premature ejaculation

Ylva Söderfeldt, Adam Droppe, Tim Ohnhäuser

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

The discovery that certain selective serotonin reuptake inhibitors delay ejaculation and the later development and approval of dapoxetine as an on-demand treatment option has led to a dramatic increase in medical interest in premature ejaculation. This paper analyses the diagnostic criteria and the discussion within the medical community about suitable treatments against the backdrop of theories of science, sex and gender. Our conclusion is that the diagnosis itself and the suggested treatments contribute to normative models of sexual conduct and therefore reinforce the norms that cause patients' distress over ejaculating 'too soon'.

Original languageEnglish
Pages (from-to)865-866
Number of pages1
JournalJournal of Medical Ethics
Volume43
Issue number12
DOIs
Publication statusPublished - 2017
Externally publishedYes

Swedish Standard Keywords

  • Pharmacology and Toxicology (30102)

Keywords

  • Concept of Health
  • Drugs and Drug Industry
  • Sexuality/Gender

Fingerprint

Dive into the research topics of 'Distress, disease, desire: perspectives on the medicalisation of premature ejaculation'. Together they form a unique fingerprint.

Cite this